563 related articles for article (PubMed ID: 29524296)
1. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.
Kapodistria K; Tsilibary EP; Kotsopoulou E; Moustardas P; Kitsiou P
J Cell Mol Med; 2018 Jun; 22(6):2970-2980. PubMed ID: 29524296
[TBL] [Abstract][Full Text] [Related]
2. Nephrin, a transmembrane protein, is involved in pancreatic beta-cell survival signaling.
Kapodistria K; Tsilibary EP; Politis P; Moustardas P; Charonis A; Kitsiou P
Mol Cell Endocrinol; 2015 Jan; 400():112-28. PubMed ID: 25448064
[TBL] [Abstract][Full Text] [Related]
3. Protective action of liraglutide in beta cells under lipotoxic stress via PI3K/Akt/FoxO1 pathway.
Shao S; Nie M; Chen C; Chen X; Zhang M; Yuan G; Yu X; Yang Y
J Cell Biochem; 2014 Jun; 115(6):1166-75. PubMed ID: 24415347
[TBL] [Abstract][Full Text] [Related]
4. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
Moffett RC; Patterson S; Irwin N; Flatt PR
Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
[TBL] [Abstract][Full Text] [Related]
5. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
6. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
7. The Akt/FoxO1/p27 pathway mediates the proliferative action of liraglutide in β cells.
Fang D; Huang Z; Guan H; Liu J; Yao B; Xiao H; Li Y
Mol Med Rep; 2012 Jan; 5(1):233-8. PubMed ID: 21964769
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice.
Tamura K; Minami K; Kudo M; Iemoto K; Takahashi H; Seino S
PLoS One; 2015; 10(5):e0126003. PubMed ID: 25938469
[TBL] [Abstract][Full Text] [Related]
9. High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells.
Venieratos PD; Drossopoulou GI; Kapodistria KD; Tsilibary EC; Kitsiou PV
Cell Signal; 2010 May; 22(5):791-800. PubMed ID: 20067833
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.
Kimura T; Kaneto H; Shimoda M; Hirukawa H; Okauchi S; Kohara K; Hamamoto S; Tawaramoto K; Hashiramoto M; Kaku K
Mol Cell Endocrinol; 2015 Jan; 400():78-89. PubMed ID: 25463759
[TBL] [Abstract][Full Text] [Related]
11. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
12. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.
Shimoda M; Kanda Y; Hamamoto S; Tawaramoto K; Hashiramoto M; Matsuki M; Kaku K
Diabetologia; 2011 May; 54(5):1098-108. PubMed ID: 21340625
[TBL] [Abstract][Full Text] [Related]
13. Puerarin Protects Pancreatic β-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling.
Yang L; Yao D; Yang H; Wei Y; Peng Y; Ding Y; Shu L
Mol Endocrinol; 2016 Mar; 30(3):361-71. PubMed ID: 26789107
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.
Friedrichsen BN; Neubauer N; Lee YC; Gram VK; Blume N; Petersen JS; Nielsen JH; Møldrup A
J Endocrinol; 2006 Mar; 188(3):481-92. PubMed ID: 16522728
[TBL] [Abstract][Full Text] [Related]
15. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
Zheng J; Chen T; Zhu Y; Li HQ; Deng XL; Wang QH; Zhang JY; Chen LL
Exp Biol Med (Maywood); 2015 Sep; 240(9):1165-76. PubMed ID: 25710926
[TBL] [Abstract][Full Text] [Related]
17. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway.
Xu X; Chen J; Hu L; Liang M; Wang X; Feng S; Shen J; Luan X
Life Sci; 2018 Feb; 195():87-94. PubMed ID: 29225111
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K/Akt/caspase-3 signaling pathway.
Ming-Yan Y; Jing Z; Shu-Qin G; Xiao-Liang B; Zhi-Hong L; Xue Z
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31383790
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide.
Lampropoulou E; Lymperopoulou A; Charonis A
Metabolism; 2016 Jan; 65(1):7-15. PubMed ID: 26683792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
